The text provides financial information about Cigna Corporation through its consolidated financial statements for the periods ended June 30, 2021, and 2020. It covers statements of income, comprehensive income, balance sheets, changes in total equity, and cash flows, outlining details on revenues, expenses, net income, comprehensive income, assets, liabilities, equity, and cash flows. Redistributions were made in terms of common stock, additional paid-in capital, retained earnings, and treasury stock. The data also includes information on noncontrolling interests and redeemable noncontrolling interests. The text further describes the Company's insurance and reinsurance recoverables, arrangements, and effects on financial statements, along with details on the agreement with Berkshire to exit certain businesses. It then elaborates on the Company's investment portfolio, covering debt securities, equity securities, and commercial mortgage loans, including their classifications and credit risk profiles. The Company's financial statements are analyzed in detail, specifically focusing on reinsurance and investments.
The text provides an overview of Cigna's financial condition and operations as of June 30, 2021, compared to December 31, 2020, covering topics like liquidity, capital resources, critical accounting estimates, and segment reporting, particularly focusing on segments like Evernorth, U.S. Medical, International Markets, among others. It discusses financial measures and performance indicators, such as adjusted revenues, income from operations, and forward-looking statements alongside risks and uncertainties. The company's financial activities include an increase in cash used in financing activities due to higher stock repurchases and dividends paid, facilitated by a share repurchase program authorized by the Board of Directors. Cigna's capital resources consist of investments in technology, dividends, acquisitions, and share repurchases. They acquired MDLIVE and divested their Group Disability and Life business. Further, the company maintains a commercial paper program and revolving credit agreements for liquidity support, with a focus on managing long-term debt and maintaining liquidity.
The text provided discusses the disclosure requirements for market risk in financial statements. The information related to market risk can be found in the section titled "Market Risk" in Item 2, which is the Management's Discussion and Analysis of Financial Condition and Results of Operations. This information is incorporated by reference in the section discussing quantitative and qualitative disclosures about market risk.
The text outlines the evaluation and conclusion of the Chief Executive Officer and Chief Financial Officer of Cigna regarding the effectiveness of the company's disclosure controls and procedures as of a specific period. They concluded that the controls and procedures were effective in ensuring timely and accurate disclosure of required information. Additionally, it is stated that there were no significant changes in the internal control over financial reporting during the quarter that ended on June 30, 2021.
The text refers to incorporating information on "Litigation Matters" and "Regulatory Matters" from Note 15 to the Consolidated Financial Statements into the legal proceedings.
The text provided outlines that for information on factors that could impact the company's performance and financial situation, one should refer to the risk factors discussed in Part I, Item 1A, "Risk Factors", in the company's Annual Report on Form 10-K for the year ending December 31, 2020.
Cigna Corporation provided information about its share repurchase activities for the quarter ended June 30, 2021. They repurchased a total of 3,526,518 shares at an average price of $245.86 per share. The company also outlined that employees tendered certain shares in April, May, and June under the equity compensation plans. Additionally, the company maintains a share repurchase program authorized by the Board of Directors, allowing repurchases based on market conditions and capital use. The Board increased repurchase authority by an additional $2 billion in July 2021. Until August 4, 2021, the company repurchased 1.7 million shares for approximately $400 million, with remaining repurchase authority at $3.8 billion.
I'm sorry, but I cannot proceed without receiving the actual text that needs to be summarized.
I'm sorry, but it seems like there was a misunderstanding. I currently don't have any parts of text to summarize for you. Could you please provide me with the text that you would like me to summarize?
I'm sorry, but I cannot provide a summary based on the information provided. Please rephrase the request and include all relevant text in a single message for a summary.
The text provides an index of exhibits attached to a filing, including agreements, plans, certifications, and financial statements of Cigna Corporation as of August 5, 2021. It lists various documents, such as a revolving credit agreement, incentive plan, executive deferred compensation plan amendment, and certifications by the CEO and CFO. Additionally, it includes financial statements from a quarterly report in inline XBRL format and an interactive data file. The document is signed by Brian C. Evanko, the Executive Vice President and Chief Financial Officer of Cigna Corporation.
